 |
2021 News Releases
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, Calif., Feb. 9, 2021 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a
biopharmaceutical company, announced that on February 4, 2021 the Compensation Committee of Puma’s
Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of
11,000 shares of Puma common stock to two new non-executive employees.
The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was
adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The
restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each
award vesting on the first anniversary of the award’s vesting commencement date, February 1, 2021, and
one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting
commencement date thereafter, subject to continued service. The awards were granted as an inducement
material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing
Rule 5635(c)(4).
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and
commercialization of innovative products to enhance cancer care. Puma in-licenses the global development
and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant
treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following
adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib)
tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine
for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have
received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted
marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult
patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who
are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a
registered trademark of Puma Biotechnology, Inc.
Contact:
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
# # # # #
Back to 2021 News Releases
|
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
|
